NCT06433830View on ClinicalTrials.gov

Hetrombopag for the Thrombocytopenia Induced by Concurrent Chemoradiotherapy

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

May 10, 2022

Primary Completion Date

May 30, 2025

Study Completion Date

July 30, 2025

Conditions
ThrombocytopeniaRadiotherapy Side Effect
Interventions
DRUG

Hetrombopag Olamine

The administration of hetrombopag as a monotherapy and at an initial dose of 7.5 mg QD.The dose adjusted based on platelet count.

Trial Locations (1)

310016

RECRUITING

Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
lead

Sir Run Run Shaw Hospital

OTHER